Cargando…
Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable acti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306925/ https://www.ncbi.nlm.nih.gov/pubmed/25548974 http://dx.doi.org/10.3390/md13010065 |
_version_ | 1782354386012340224 |
---|---|
author | Wahome, Paul G. Beauchesne, Kevin R. Pedone, Anna C. Cavanagh, John Melander, Christian Zimba, Paul Moeller, Peter D. R. |
author_facet | Wahome, Paul G. Beauchesne, Kevin R. Pedone, Anna C. Cavanagh, John Melander, Christian Zimba, Paul Moeller, Peter D. R. |
author_sort | Wahome, Paul G. |
collection | PubMed |
description | Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable activity may be reduced or eliminated by using lower doses of the cytotoxic compound in combination with another compound that modulates its activity. Here, we have examined the cytotoxicity of four microbial metabolites [ethyl N-(2-phenethyl) carbamate (NP-1), Euglenophycin, Anabaenopeptin, and Glycolipid 652] using three in vitro cell lines [human breast cancer cells (MCF-7), mouse neuroblastoma cells (N2a), and rat pituitary epithelial cells (GH4C1)]. The compounds showed variable cytotoxicity, with Euglenophycin displaying specificity for N2a cells. We have also examined the modulatory power of NP-1 on the cytotoxicity of the other three compounds and found that at a permissible concentration (125 µg/mL), NP-1 sensitized N2a and MCF-7 cells to Euglenophycin and Glycolipid 652 induced cytotoxicity. |
format | Online Article Text |
id | pubmed-4306925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-43069252015-02-02 Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant Wahome, Paul G. Beauchesne, Kevin R. Pedone, Anna C. Cavanagh, John Melander, Christian Zimba, Paul Moeller, Peter D. R. Mar Drugs Communication Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable activity may be reduced or eliminated by using lower doses of the cytotoxic compound in combination with another compound that modulates its activity. Here, we have examined the cytotoxicity of four microbial metabolites [ethyl N-(2-phenethyl) carbamate (NP-1), Euglenophycin, Anabaenopeptin, and Glycolipid 652] using three in vitro cell lines [human breast cancer cells (MCF-7), mouse neuroblastoma cells (N2a), and rat pituitary epithelial cells (GH4C1)]. The compounds showed variable cytotoxicity, with Euglenophycin displaying specificity for N2a cells. We have also examined the modulatory power of NP-1 on the cytotoxicity of the other three compounds and found that at a permissible concentration (125 µg/mL), NP-1 sensitized N2a and MCF-7 cells to Euglenophycin and Glycolipid 652 induced cytotoxicity. MDPI 2014-12-26 /pmc/articles/PMC4306925/ /pubmed/25548974 http://dx.doi.org/10.3390/md13010065 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Wahome, Paul G. Beauchesne, Kevin R. Pedone, Anna C. Cavanagh, John Melander, Christian Zimba, Paul Moeller, Peter D. R. Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
title | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
title_full | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
title_fullStr | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
title_full_unstemmed | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
title_short | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
title_sort | augmenting anti-cancer natural products with a small molecule adjuvant |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306925/ https://www.ncbi.nlm.nih.gov/pubmed/25548974 http://dx.doi.org/10.3390/md13010065 |
work_keys_str_mv | AT wahomepaulg augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT beauchesnekevinr augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT pedoneannac augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT cavanaghjohn augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT melanderchristian augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT zimbapaul augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT moellerpeterdr augmentinganticancernaturalproductswithasmallmoleculeadjuvant |